Back to

@Vaccines to show progress against Ebola

This week, for the first time, @Vaccines is curated by a representative of a vaccine manufacturer.

Dr. Van Hoof is Global Head of Janssen Vaccines, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. He is the leader of Janssen’s Ebola vaccine development initiatives. Dr. Van Hoof formerly represented the International Federation of Pharmaceutical Manufacturers & Associates on the board of Gavi. He acquired over 20 years of vaccine industry experience at Pasteur Mérieux Connaught, Chiron Vaccines, and GlaxoSmithKline Biologicals.  He has been actively involved in the development and licensing of new generations of childhood and adult vaccines for haemophilus Influenzae b, pertussis, meningitis, rotaviral diarrhea, hepatitis, flu, and HPV.

In the 40 years since the discovery of the Ebola virus, 25 outbreaks have occurred. Tweeting from the 8th International Symposium on Filoviruses in Antwerp, Belgium, Dr. Van Hoof will share how the pharmaceutical industry is striving to develop Ebola vaccines before the next outbreak.

Subscribe to our newsletter